These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37673061)

  • 1. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials.
    Rosenstock J; Vázquez L; Del Prato S; Franco DR; Weerakkody G; Dai B; Landó LF; Bergman BK; Rodríguez A
    Diabetes Care; 2023 Nov; 46(11):1986-1992. PubMed ID: 37673061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
    Zeitler P; Galindo RJ; Davies MJ; Bergman BK; Thieu VT; Nicolay C; Allen S; Heine RJ; Lee CJ
    Diabetes Care; 2024 Jun; 47(6):1056-1064. PubMed ID: 38639997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
    Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
    Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
    Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
    Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.
    Bao Y; Han L; Du L; Ji L
    Obesity (Silver Spring); 2024 Jun; 32(6):1102-1113. PubMed ID: 38803303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
    Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
    Małecki MT; Batterham RL; Sattar N; Levine JA; Rodríguez Á; Bergman BK; Wang H; Ghimpeteanu G; Lee CJ
    Diabetes Care; 2023 Dec; 46(12):2292-2299. PubMed ID: 37824793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
    Lingvay I; Mosenzon O; Brown K; Cui X; O'Neill C; Fernández Landó L; Patel H
    Cardiovasc Diabetol; 2023 Mar; 22(1):66. PubMed ID: 36964557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
    Pedersen SD; Giorgino F; Umpierrez G; Thieu VT; Rodríguez A; Nicolay C; Fernández Landó L; Karanikas CA; Kiljanski J
    Diabetes Obes Metab; 2023 Sep; 25(9):2553-2560. PubMed ID: 37246796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Ma J; Liu M; Wang R; Du L; Ji L
    Diabetes Obes Metab; 2024 Apr; 26(4):1454-1463. PubMed ID: 38302718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
    Bi Y; Lu S; Tang J; Du L; Ji L
    Diabetes Ther; 2024 May; 15(5):1125-1137. PubMed ID: 38494574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
    Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
    Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
    Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.